|
|
Article: Big Pharma & Biotech - Zacks Analyst Interviews
- Article from:
- Zacks Investment Research - Zacks Analyst Interviews
- Article date:
- November 10, 2009
- Author:
CopyrightCopyright 2009 Zacks Investment Research. (Hide copyright information)
|
Big Pharma & Biotech - Zacks Analyst Interviews
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to
IMS Health
(
RX
), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition, including Lipitor, ...